Member Info for doze

What about paying back the cost of the drilled wells. "The Company has been in continuous dialogue with the PRC Government and its controlled entities China National Offshore Oil (CNOOC), CNPC, PetroChina and China United Coalbed Methane Corporation (CUCBM) regarding their drilling activities across the Company's PSC blocks", without the team to take these wells over a lot of expense is going to be incurred hence the evaluation of future production once the judicial deliberations are over.

Furthermore, until such information is ascertained, we will prudently suspend any aggressive drilling campaign or related financings, so as to absorb all of this material information. Additionally, our experienced technical staff will also account for the well type drilled in these campaigns and we will adjust our efficient and proven LiFaBriC wells patterns to accommodate the findings. We are committed to amicably concluding the material impact within our PSC areas in various aspects and look forward to capitalizing on this accelerated development to significant commerciality. However, we stand ready to enforce our PSC rights in the event there is any procrastination on such a mutually beneficial conclusion." http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11734841 ........................................ This might mean less work for GEL until repercussions of enforcement are sorted out and new production plan formulated by GDG. I hope it will send the GDG price up as I kept my shares and they have got to rise a bit, but looks like they will.

aAll comments welcomed when they arrive.

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11733318 The Company received notification on 4 October 2013 that, Alan Reade, Non-Executive Chairman of the Company, purchased on that date 675,000 common shares of US$0.001 in the Company ("Common Shares") at a price of 5 pence per share. 227,000 of the Common Shares purchased were purchased in Alan Reade's wife's name. Following this transaction, Alan Reade is beneficially interested in 10,486,358 Common Shares representing an interest of 6.25 per cent of the total voting rights of the Company. In addition, Alan Reade is interested in 2,645,695 stock appreciation right options over Common Shares as follows: Options Held Option Exercise Price Expiry Date 1,000,000 6p 25 April 2022 100,570 12p 6 March 2022 550,000 10.5p 4 February 2020 995,125 12p 20 October 2020

HMP's current clinical pipeline includes: Fruquintinib, Sulfatinib, Epitinib, Theliatinib and Volitinib, each of which has the potential to treat a number of cancers, and HMPL-004, its lead candidate for ulcerative colitis and Crohn's disease. In addition, HMP has formed key partnerships with major global pharmaceutical companies, including AstraZeneca and Nestlé Health Science. The briefing will also cover HMP's pre-clinical research and the ongoing Phase III clinical development of HMPL-004, which is being undertaken by Nutrition Science Partners, a 50:50 joint venture between Chi-Med and Nestlé Health Science. During the briefing, Dr Andrew Mortlock, Vice President of Cancer Research and Development Projects of AstraZeneca will give a presentation entitled, "Oncology in China".

Aberdeen Global - Asian Smaller Companies Fund by virtue of there GDG holding http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11731248

rob, I am not going to engage with you on recommendations, it is easy to see where I have an interest and am winning/losing by clicking on my moniker. One of the most necessary attributes of an investor is conquering ones emotions and I maintain anyone can make money in their own way/style choosing from the many tactics employable. Anyway I am still very much a learner and all my choices are tips from other people which I have to make my own and that is how I learn. I have actually spoken to PLE employee at MasterInvestor, it has done well recently. I don't know about DSG but the old brain can only take so much research. Chan is a better investor to follow and I recently followed him into RST seeing it as a solid firm and with a local outpost near me. ATB doze

Just slightly up on my GDG buy when taking account of SP here, I think they could do well.

reading the Wiki link, they chose to list on AIM, it may not have the following it use to with the lashings it gets from the likes of Tom Winnifrith but I think the investors in Britain are the most competent in the world so who wouldn't want to list here if they are a going concern.

It makes you proud to be a part owner

3 GEL for every 1 GDG

Thankyou folks but it was only a rns which I like to record if I am invested, as I am here. I think it is a better side of entertainment to be in than running a TV station.

http://www.theguardian.com/business/marketforceslive/2013/sep/26/lord-ashcroft-share-sale-aim-restore

I didn't know that, he backed a good horse! I was wondering who the 43.6% went to after disposal. I am expecting a holding rns, the responsibility of the buyer I believe.

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11721598 I wonder who has the 43.6%/any notifiables?

Agreed,I bought more, now, what to sell.........

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11720104 Phil Reason, CEO of Instem plc, commented: "We are very pleased with Instem's strategic, operational and financial progress in the first half of the year. We have continued to broaden our product range, extend our geographical reach and sign top tier clients across the breadth of our expanded product set. In addition, Instem also made an important move into the early phase clinical market through the acquisition of Logos Technologies, which has already proven beneficial. Both the regulatory and fiscal environments continue to be favourable to Instem, driving demand for all areas of our product suite. With a strong order intake in the first half, the Board continues to view the future prospects for the business with confidence." Instem is a robust business, with net cash and a valuable blue-chip customer base delivering high levels of recurring revenue. We believe Instem has bolstered its already strong position, and is well placed to take advantage of the structural changes in the processes of drug development that are currently taking place, which should drive further growth in global demand across our expanded product set.

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11720107

http://www.investegate.co.uk/eservglobal-limited/esg/eservglobal-announces-project-with-indosat/201309170700131274O/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=eServGlobal%20Limited%20Alert "eServGlobal's leading recharge software and innovative solutions will form an integral part of our offering for years to come as we continue to launch new services across Indonesia," said Alexander Rusli, President Director & CEO, Indosat. Indosat is majority owned by the Ooredoo Group (formerly Qtel) which has over 92 million customers across its operations in the Middle East, North Africa, the Asia Subcontinent and South-East Asia.

http://www.lse.co.uk/share-media.asp?shareprice=TRT&share=transense_tech